Our CEO/CSO Luigi Aurisicchio has been invited to the event “Lazio2030: insieme per innovare”, because Takis is among the companies that have successfully used regional support to invest in research and innovation.

Since we have decided to invest and create innovation and employment in Lazio region, we have managed to keep the excellent reputation of Italian research by bringing new therapeutic solutions for cancer patients into pre-clinical and clinical stages.

To learn more about Takis’ Rever3mAb, MenHub, High Throughput mAbs, click here ...

To learn more about GENEVAX, led by Evvivax Spin off, click here ...

We are proud to have become part of this community and never going to stop believing in the value of scientific research.